Regulatory Approvals

Biopharma bites: Full FDA approval for Fabhalta, plus Dimerix’s renal buy

By

Regulatory Approvals — Biopharma bites: Full FDA approval for Fabhalta, plus Dimerix's renal buy  FirstWord PHARMA

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. July 18, 2026.

By

Related Post

Regulatory Approvals

Dr Galsky on the FDA Approval of Pembrolizumab Plus Enfortumab Vedotin in MIBC

Regulatory Approvals

FDA approves new pill to lower cholesterol levels

Regulatory Approvals

FDA approves breakthrough daily pill for cholesterol

Financial News For All

Business Economy Finance

Commodities Price Update: Crude Oil $81.78, Brent $88.10, Copper $6.27, Coal $104.75 — Jul 18, 2026 11:00 AM EDT

Artificial Intelligence Technology

Kimi K3 Puts a Price on the Frontier — and a Target on Closed-Model Margins

Product Recalls

Khong Guan Corporation Issues Recall of Glutinous Rice Balls With Black Sesame Filling Due to Undeclared Peanuts

Product Recalls

Taylor Fresh Foods Recalls Iceberg Lettuce from Central Mexico Because of Possible Health Risk